M Naomi Horiba

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Irritable Bowel Syndrome

Ejection Fraction

Locally Advanced

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Sandra J Casak, M Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J Lemery, Yuan Li Shen, Wentao Fu, Jason N Moore, Yangbing Li, Youwei Bi, Doris Auth, Nataliya Fesenko, Paul G Kluetz, Richard Pazdur, Lola A Fashoyin-Aje
FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
M Naomi Horiba, Sandra J Casak, Pallavi S Mishra-Kalyani, Pourab Roy, Julia A Beaver, Richard Pazdur, Paul G Kluetz, Steven J Lemery, Lola A Fashoyin-Aje
FDA Approval Summary: Nivolumab for adjuvant treatment of adults with completely resected esophageal/gastroesophageal junction cancer and residual pathologic disease. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Timil H Patel, Leigh Marcus, M Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S Mishra-Kalyani, Robert N Schuck, Yangbing Li, Xinyuan Zhang, Jeanne F Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J Lemery, Richard Pazdur, Marc R Theoret, Lola A Fashoyin-Aje
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)